High cross-reactivity of hypervariable region 1 antibody of hepatitis C virus is associated with early virological response in chronic hepatitis C patients undergoing antiviral therapy
2012
Objective
To discuss the relationship between the cross-reactivity of antibody against the hypervariable region 1(HVR1) of hepatitis C virus and early viral response (EVR) in patients undergoing antiviral therapy.
Methods
By ELISA and HCV HVR1 antibody cross-reactivity matrix reagent, the differences of anti-HCV hypervariable region antibody were tested in baseline serum from 46 patients with chronic hepatitis C before antiviral therapy.HCV genotyping and HCV RNA were analyzed by RT-PCR method.The HCV RNA assay was done at three time points: before treatment, pegylated interferon in combination with ribavirin therapy for 12 and 48 weeks.
Results
In 46 cases of chronic hepatitis C patients, there were 16 cases with HCV 2a type, 30 cases with 1b and 33 patients obtained EVR.The EVR incidence of type 2a[93.8%(15/16)]was higher than that of type 1b[60.0%(18/30),χ2=4.316,P<0.05].In the EVR group of type 1b chronic hepatitis C patients, the positive number of average multi-target HVR1 antigen was (12±4), which was significantly higher than that in the Non-EVR patients [(7±5),t=2.797,P<0.01].By the Fisher exact test, it was showed that patients'serum response to HVR1 antigens numbered 001, 003, 009, 013, 016 were higher in EVR group than those in non-EVR group, with statistically significant (P<0.05).
Conclusion
The cross-reactivity of HVR1 antibody may play an important role in predicting the effectiveness of antiviral therapy.(Chin J Lab Med,2012,35:630-633)
Key words:
Hepatitis C virus; Hypervariable region 1; Cross-reactivity; Quasipecies; Antiviral therapy
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI